Profile

Hi All, I'm working through our institution's subcutaneous amivantamab treatment plan with it's recent approval and I wanted to see what everyone else's approach has been to post-C1D1 monitoring? Technically the package insert does not recommend any specific period of monitoring, however, there ...

Hi all - was curious if anyone's heard any recent updates regarding sunvozertinib access or have been successful in getting it at their institution? Best, -kevin

Hi Kate, Sounds like a tricky situation. Agree with Lauren that these exon18 mutations may respond better to second-generation EGFR TKIs. There's some in-vitro data suggesting that the E709_T710delinsD may actually be more afatinib sensitive than the other more exon18 mutations seen such as G719X (h ...

We're still admitting patients for the first 2 doses as our initial patient experiences after FDA approval had significantly higher rates of ICANS than was reported in trials, so we were hesitant to shift towards outpatient monitoring. That said - the emerging 6-8h data from the DeLLphi-300 & 304 trials ...

Hi All, Wanted to see if y'all saw this study from ASCO regarding ICI timing: https://ascopubs.org/doi/abs/10.1200/JCO.2025.43.16_suppl.8516?af=R What do you think of this data? Have you talked to your providers about it? How could this be implemented in practice? -Kevin ------------------------------ ...